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RESEARCH ARTICLE Open Access
Are large clinical trials in orthopaedic
trauma justified?
Sheila Sprague1,2*, Paul Tornetta III3, Gerard P. Slobogean4, Nathan N. O’Hara4, Paula McKay2, Brad Petrisor1,
Kyle J. Jeray5, Emil H. Schemitsch6, David Sanders6, Mohit Bhandari1,2 and on behalf of the FLOW Investigators
Abstract
Background: The objective of this analysis is to evaluate the necessity of large clinical trials using FLOW trial data.
Methods: The FLOW pilot study and definitive trial were factorial trials evaluating the effect of different irrigation
solutions and pressures on re-operation. To explore treatment effects over time, we analyzed data from the pilot
and definitive trial in increments of 250 patients until the final sample size of 2447 patients was reached. At each
increment we calculated the relative risk (RR) and associated 95% confidence interval (CI) for the treatment effect,
and compared the results that would have been reported at the smaller enrolments with those seen in the final,
adequately powered study.
Results: The pilot study analysis of 89 patients and initial incremental enrolments in the FLOW definitive trial favored
low pressure compared to high pressure (RR: 1.50, 95% CI: 0.75–3.04; RR: 1.39, 95% CI: 0.60–3.23, respectively), which is
in contradiction to the final enrolment, which found no difference between high and low pressure (RR: 1.04, 95% CI: 0.
81–1.33). In the soap versus saline comparison, the FLOW pilot study suggested that re-operation rate was similar in
both the soap and saline groups (RR: 0.98, 95% CI: 0.50–1.92), whereas the FLOW definitive trial found that the
re-operation rate was higher in the soap treatment arm (RR: 1.28, 95% CI: 1.04–1.57).
Conclusions: Our findings suggest that studies with smaller sample sizes would have led to erroneous conclusions in
the management of open fracture wounds.
Trial registration: NCT01069315 (FLOW Pilot Study) Date of Registration: February 17, 2010, NCT00788398 (FLOW
Definitive Trial) Date of Registration: November 10, 2008.
Keywords: Large trials, Orthopaedic trial, Sample size, FLOW trial
Background
Large definitive clinical trials in orthopaedic trauma are
expensive, challenging, and time consuming to conduct.
In times of limited research funding, their value may be
called into question as it costs several million dollars to
answer one or two clinical questions and results may not
be translated into practice for five to eight years following
initiation of the trial [1]. However, it is equally important
to consider that smaller trials may be inadequately
powered to answer clinical questions or have fragility in
their results, potentially leading to an over or underesti-
mation of the true treatment effect. Small studies are sub-
ject to Beta error, which is to say that no difference is
found even though one may exist. While this is considered
a less egregious error than a false finding of a difference in
treatments, if one treatment is in fact better than another
and this is not found due to small sample size, an oppor-
tunity to improve patient care is missed.
Previous research has demonstrated that it is not uncom-
mon for the results of highly cited clinical studies published
in high impact medical journals to be contradicted by the
findings of subsequent studies [2]. Randomized controlled
trials (RCTs) are not immune from having their findings
contradicted by subsequent studies, with small RCTs being
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at higher risk than larger ones of having their findings con-
tradicted by subsequent trials [2, 3]. The objective of this
study is to evaluate the value of one large clinical trial in
orthopaedic trauma using data from the FLOW trial.
Methods
This investigation was part of the multi-centre FLOW
(Fluid Lavage in Open Fracture Wounds) initiative. As a
means of proving feasibility and testing the FLOW proto-
col, we completed the FLOW pilot study. The FLOW
pilot study was a 2 × 2 factorial design which evaluated
irrigation solution (soap vs. normal saline) and irrigation
pressure (low vs. high) in patients with open fracture
wounds. The FLOW pilot study included 89 patients at
nine clinical sites in Canada and the United States. The re-
sults of the FLOW pilot study (ClinicalTrials.gov number,
NCT01069315) informed the development of the FLOW
definitive trial (ClinicalTrials.gov number, NCT00788398),
which was a multi-center, blinded, randomized controlled
trial, using a 2 × 3 factorial design which evaluated irriga-
tion solution (soap vs. normal saline) and irrigation pres-
sure (very low vs. low vs. high) in patients with open
fracture wounds [4]. The FLOW definitive trial included
2447 patients across 41 clinical sites in the United States,
Canada, Australia, Norway, and India [5]. The primary
outcome for the FLOW pilot and definitive studies was
re-operation within 12 months of fracture to treat infec-
tion or promote wound or fracture healing. Research
Ethics Board (REB) Approval for the FLOW pilot and
definitive trial was obtained at the coordinating centre
(McMaster University) (REB: 05–299 and 08–268) and at
each clinical site. All procedures followed were in accord-
ance with ethical standards of the ethics boards.
To evaluate the value of a trial of this size, we analyzed
the data from the pilot study and then the definitive trial
in increments of 250 patients until the final sample size
was reached. Increments of 250 were selected for ease of
reporting and to reflect what the findings would have been
for a trial of each incremental size. At each increment, we
calculated the relative risk (RR) and associated 95% confi-
dence interval (CI) for the treatment effect. We then com-
pared the results that would have been reported at the
smaller enrolments with those seen in the final, adequately
powered study. All analyses were performed using JMP
Version 12.0 (Cary, NC).
Results
In the soap versus saline comparison, data from the
FLOW pilot study suggested that a small benefit to irriga-
tion with soap may exist (RR: 0.98, 95% CI: 0.50–1.92, p =
0.82). However, the wide confidence intervals on each side
of the relative risk indicated similar likelihood that soap or
saline could be more efficacious. These preliminary results
based on a very small sample size were sharply contrasted
by the larger definitive FLOW trial which found that the
risk of re-operation was higher in the soap treatment arm
(RR: 1.28, 95% CI: 1.04–1.57, p = 0.02) (Fig. 1). The results
achieved statistical significance (with the lower confidence
interval for the relative risk being greater than one) when
1500 patients were enrolled into the trial (p = 0.02). As ex-
pected, the confidence intervals narrowed as the final
sample size of 2447 was reached.
The results of all three pressure comparisons demon-
strated similar patterns in which the initial increments
of patients favored one pressure over another but the
final enrolment of 2447 patients found no difference
Fig. 1 Effect of soap vs. saline on FLOW trial patients at different sample sizes
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between irrigation pressure treatment groups (Figs. 2, 3
and 4). For example, the pilot study analysis of 89
patients favored low pressure compared to high pressure
irrigation (RR: 1.50, 95% CI: 0.75–3.04 (p = 0.14) (Fig. 2).
The initial incremental enrolments in the definitive trial
also favored low pressure compared to high pressure (e.
g. n = 250, RR: 1.39, 95% CI: 0.60–3.23, p = 0.48). When
750 patients were enrolled into the trial, the difference
approached significance with p = 0.06 (RR = 1.55, 95%
CI: 0.99–2.41). This is in contradistinction to the final
enrolment of 2447 that found no difference between high
and low pressure (RR: 1.04, 95% CI: 0.81–1.33, p = 0.82).
Similarly, the initial increment of 250 patients favored
very low pressure over high pressure (RR: 1.10, 95% CI: 0.
52–2.36, p = 0.83) (Fig. 3), and low pressure over very low
pressure (RR: 1.26, 95% CI: 0.54–2.98, p = 0.63) (Fig. 4).
However, in both cases, the final enrolment demonstrated
no differences between any of the irrigation pressures.
Discussion
Our findings suggest that both the results of the FLOW
pilot study and selecting a smaller sample size for the
FLOW definitive trial would have led to erroneous con-
clusions in the management of open fracture wounds.
With regard to the results of one of the major research
questions, namely whether irrigation with soap reduced
the re-operation rate, the point estimate changes from
potentially favoring soap to demonstrating that irrigation
with soap is a risk factor for re-operation in the final
enrollment increments of the definitive trial. At lower
Fig. 2 Effect of high vs. low pressure on FLOW trial patients at different sample sizes
Fig. 3 Effect of high vs. very low pressure on FLOW trial patients at different sample sizes
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enrolment increments, comparisons between different
pressures initially favored low pressure over both high and
very low pressure, and very low pressure over high
pressure. However, no differences between any of the
irrigation pressures were observed at the final enrolment
of 2447 patients. Most notably, at 750 patients, the results
came very close to demonstrating a significant difference
favoring low pressure over high pressure despite the fact
that no significant differences were observed at higher
enrolment increments.
When interpreting these results, it is important to con-
sider that we analyzed the data in sequential increments of
250 patients. Since the number of clinical sites and partici-
pating surgeons increased with increasing sample size,
differences in performance variables between sites and
surgeons may have contributed to the observed differences
in outcomes. If we had repeated these analyses using
randomly selected subsets of patients, the results may have
been quite different. However, this approach would not
have represented an accurate reflection of the number of
centers, participating surgeons, or enrollment timelines
typically associated with smaller RCTs.
The sample size for the pilot study (n = 89) was chosen
to inform the design of a large definitive trial and demon-
strate to large funding agencies that the selected method-
ology was feasible. We published the results of the FLOW
pilot study to generate interest and promote the definitive
trial among the orthopaedic trauma community. We did
not publish the pilot study results with the goal of chan-
ging clinical practice. Had this been our intent, erroneous
treatment recommendations would have been made. In
contrast, the sample size for the FLOW definitive trial was
based on a sample size calculation, where we carefully
considered realistic a priori event rates and corresponding
reductions in relative risks between the treatment groups
based upon the previous literature and the opinion of
multiple experts [4].
The FLOW study was a factorial study and the advan-
tages of a factorial design over a standard parallel group de-
sign include the ability to efficiently investigate a minimum
of two interventions and the reduction in the total number
of patients needed to assess multiple interventions aimed at
achieving the same outcome. If we had not used a factorial
study, the sample size for an adequately powered study,
using the assumptions described above, comparing soap
versus saline would have been 1200 patients (600 patients
per treatment arm). Similarly, a separate study comparing
high versus low versus very low pressure would have re-
quired 2280 patients (760 per treatment arm). Conse-
quently, answering the two research questions in two
separate studies would have required 3480 patients, dem-
onstrating the efficiency of a factorial design.
As demonstrated in Figs. 1, 2, 3 and 4, it is evident that
the results of the FLOW study appear to stabilize before
the final enrolment of 2447 patients. Specifically, in the
soap versus saline comparison the results seem to stabilize
around 1200 patients, which is consistent with the above
sample size calculation. The results for the comparisons
between the three irrigating pressures seem to stabilize
following the enrolment of approximately 2000 patients.
One may question whether we enrolled too many patients
into the FLOW trial. The answer is “no” as this stabilization
occurred because the overall FLOW study sample size was
calculated based upon the three pairwise comparisons for
the pressures, however, in the end, the hypothesized differ-
ences between pressures were not observed. Had the results
of the FLOW trial shown our hypothesized differences, it is
possible that this stabilization would not have occurred
until closer to the final sample size. In order to explore
treatment effects over time, we have analyzed the data from
Fig. 4 Effect of low vs. very low pressure on FLOW trial patients at different sample sizes
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the FLOW trial in small increments. However, if investiga-
tors conduct repeated interim analyses during the course
of a trial without adjusting the significance level, there is a
very real risk of observing a significant result merely by
chance [6]. To mitigate this risk, it is important that
investigators follow established early stopping rules that
require more stringent significance levels when conduct-
ing interim analyses.
There has been a recent focus on large RCTs among the
orthopaedic community, as evident by the Orthopaedic
Trauma Association’s decision to feature a symposium
that only included the findings from large RCTs at their
2015 Annual Meeting. Different trial groups have been
established (i.e. COTS, METRC, OTRC) with mandates of
conducting large, multi-centre RCTs. Despite this shift,
the orthopaedic literature continues to be dominated by
studies that are underpowered to guide current evidence.
While many readers understand that trials may be under-
powered, few realize that truly erroneous conclusions may
come from smaller studies, including a reversal of the ini-
tial findings. In a review of 47 highly cited research studies
published in 3 high impact medical journals, Ioannidis
found that of the 45 studies that claimed the intervention
in question was effective, seven (16%) were contradicted
by subsequent studies and seven others (16%) demon-
strated effects that were stronger than those found in
future studies [2]. Among the RCTs included in his
review, those with contradicted or stronger effects were
significantly smaller (p = 0.009) than those whose effects
were either replicated by future studies or whose findings
remained unchallenged by subsequent studies. Similar
findings have been observed within the orthopaedic litera-
ture, in that trials with smaller sample sizes and lower
event rates have been shown to observe larger treatment
effects in their results [7]. Similar to our FLOW analysis,
an analysis of data from the SPRINT trial [8] found a
smaller sample size for the SPRINT trial would have led
to misleading estimates of the relative risk of reoperation
between reamed and unreamed nails in the management
of closed tibial shaft fractures [3]. As demonstrated by the
results of the review by Ioannidis, the SPRINT analysis,
and the current analyses of the data from the FLOW trial,
readers need to consider the adequacy of the sample size
when reviewing the results of RCTs.
Specifically, readers should consider whether the sample
size calculation was based upon realistic estimates of event
rates and meaningful risk reductions. In addition, readers
should consider whether the sample size calculation is
based upon continuous outcomes (e.g. health related
quality of life) or a dichotomous outcome (e.g. re-
operation, mortality), as calculations using continuous
outcomes require smaller sample sizes (often of 80 to 120
patients). Many studies within the orthopaedic trauma
literature use continuous outcomes and have sample sizes
of approximately 100 patients, which can be sensitive to the
results of a few outlier patients [9].
Conclusions
In conclusion, the data presented from the FLOW study
highlight the need for large clinical trials in the field of
orthopaedic trauma. Researchers designing a clinical trial
need to carefully calculate the sample size to ensure that
meaningful results can be achieved to accurately guide
clinical practice. Readers of the orthopaedic trauma litera-
ture need to critically evaluate the sample size justification
as part of their decision to use clinical research to guide
the care of their patients.
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